Searched for
ALEMBIC PHARMA EARNINGS
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...- Stocks in news: Wipro, HUL, Angel One, Alembic Pharma, HDFC LifeMarkets ended flat on Thursday after a volatile session, with analysts maintaining a positive outlook and recommending a buy-on-dips strate...
- Alembic Pharma Q3 Results: Company posts 23% YoY decline in net profit at Rs 138 crore, revenue up 4%Drug maker Alembic Pharma on Monday reported Rs 138 crore net profit in Q3FY25, which is 23% year-on-year (YoY) decline compared to corresp...
- Alembic Pharma Q1 Results: Net profit rises 12% YoY to Rs 135 croreEarnings before interest, tax, depreciation and amortisation (EBITDA) rose 14% YoY to Rs 239 crore, while the EBITDA margins contracted 540...
- Alembic Pharma posts Rs 180 crore net profit in Q3FY24Drug maker Alembic Pharma on Monday reported Rs 180 crore net profit in Q3FY24, which is a 48% year-on-year (YoY) increase compared to the ...
- Alembic Pharma Q2 Results: Firm posts Rs 137-crore net profitRevenues grew 8% to Rs.1595 crore in Q2FY24 compared to Rs 1475 crore last year. The earnings before interest, tax, depreciation and amorti...
- Neutral on Alembic Pharmaceuticals, target price Rs 750: Motilal Oswal Financial ServicesAlembic Pharma delivered a better than expected operational performance, led by better-than-industry growth in the Domestic Formulations (D...
- Alembic Pharma net profit drops 40% to Rs 176 crore in Q3FY22"India business is going to grow, and continue to grow faster than our represented market, the initiatives we have taken in last few years ...
- Market Movers: Why Dr Reddy’s fell & took other drug stocks down with itThe biggest trigger for the nose bleeding fall in Dr Reddy's Labs stock was hidden away in the notes to account of the company’s P&L statem...
- Neutral on Alembic Pharma, target price Rs 1070: Motilal OswalMotilal Oswal has a neutral call on Alembic Pharmaceuticals with a target price of Rs 1070. The current market price of Alembic Pharmaceuti...
- Alembic Pharma Q3 results: Net profit rises 25% to Rs 293 croreThe company had posted a net profit of Rs 234.19 crore for the corresponding period of the previous financial year, Alembic Pharmaceuticals...
- Pharma firms discover glamour in dowdy APIsPharma companies have posted smart growth in API sales for the quarter due to increased demand of certain APIs used in the Covid-19 treatme...
- Buy Alembic Pharma, target price Rs 1,100: Yes SecuritiesStrong prognosis beyond FY22 gives tremendous support to earnings.
- Alembic Pharma Q2 PAT up 25% at Rs 250 croreThe company had posted a consolidated PAT of Rs 200.09 crore in the same quarter last fiscal.
- With several firms getting USFDA clearances, Street to breathe easy about pharma stocksLast week, Lupin, Cadila Healthcare and Alembic Pharma received clearances from the US regulator for their key facilities.
- High revenue, profit growth make Alembic analysts' favouriteAlthough both the domestic and the international businesses are doing well, the company is likely to sustain its high growth largely on acc...
- Alembic Pharmaceuticals Q3 net up 7 per cent at Rs 70.66 croreIt had posted net profit of Rs 65.93 crore in the same quarter of the 2013-14 fiscal, Alembic Pharma said in a filing to the BSE.
- Alembic Pharma: Further re-rating likely due to high growth rate, strong balance sheetAfter remaining on the sidelines for a decade, Alembic Pharma’s stock has been in the limelight in the recent past.
- Alembic Pharmaceuticals outshines pharma peers as new drugs spur growth100-year-old Vadodara-based firm, Alembic Pharmaceuticals is the second-best pharma stock in the BSE 500 in the past one year.
- Alembic Pharma holds long-term promiseOperating margin has improved from 14% a year ago to nearly 17% in the June quarter.
Load More
